Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral in vivo efficacies in humanized preclinical models
Compose a Response to This Article
Other responses
No responses have been published for this article.
